Blockchain Registration Transaction Record

Tonix Pharma to Present at Two Key Investor Conferences in May 2026

Tonix Pharmaceuticals (TNXP) announces management will attend RBC and A.G.P. conferences in May 2026. Company highlights TONMYA fibromyalgia treatment and CNS/immunology pipeline.

This news matters because Tonix Pharmaceuticals is addressing critical unmet medical needs with its recently approved fibromyalgia treatment TONMYA and a robust pipeline targeting CNS and immunology disorders. Investors and patients alike should watch for updates from these conferences, as they may provide insights into the company’s commercial strategy and clinical progress. The participation in high-profile conferences signals Tonix’s commitment to engaging with the investment community and advancing its therapies.